247 related articles for article (PubMed ID: 27669062)
21. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
22. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.
Fujimoto N; Gemba K; Asano M; Fuchimoto Y; Wada S; Ono K; Ozaki S; Kishimoto T
Respir Investig; 2013 Jun; 51(2):92-7. PubMed ID: 23790737
[TBL] [Abstract][Full Text] [Related]
23. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
24. ATG5 as biomarker for early detection of malignant mesothelioma.
Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L
BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543
[TBL] [Abstract][Full Text] [Related]
25. On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016).
Barbieri PG; Mirabelli D; Magnani C; Brollo A
Tumori; 2019 Aug; 105(4):304-311. PubMed ID: 29714657
[TBL] [Abstract][Full Text] [Related]
26. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
27. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines.
Wang Y; Hu Y; Wang D; Yu K; Wang L; Zou Y; Zhao C; Zhang X; Wang P; Ying K
Cancer Biomark; 2012; 11(4):129-37. PubMed ID: 23144150
[TBL] [Abstract][Full Text] [Related]
28. External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma.
Janssens E; Schillebeeckx E; Zwijsen K; Raskin J; Van Cleemput J; Surmont VF; Nackaerts K; Marcq E; van Meerbeeck JP; Lamote K
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804954
[TBL] [Abstract][Full Text] [Related]
29. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
30. Analysis of volatile organic compounds in the breath of patients with stable or acute exacerbation of chronic obstructive pulmonary disease.
Pizzini A; Filipiak W; Wille J; Ager C; Wiesenhofer H; Kubinec R; Blaško J; Tschurtschenthaler C; Mayhew CA; Weiss G; Bellmann-Weiler R
J Breath Res; 2018 Mar; 12(3):036002. PubMed ID: 29295966
[TBL] [Abstract][Full Text] [Related]
31. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
32. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
Tsim S; Alexander L; Kelly C; Shaw A; Hinsley S; Clark S; Evison M; Holme J; Cameron EJ; Sharma D; Wright A; Grundy S; Grieve D; Ionescu A; Breen DP; Paramasivam E; Psallidas I; Mukherjee D; Chetty M; Cox G; Hart-Thomas A; Naseer R; Edwards J; Daneshvar C; Panchal R; Munavvar M; Ostroff R; Alexander L; Hall H; Neilson M; Miller C; McCormick C; Thomson F; Chalmers AJ; Maskell NA; Blyth KG
J Thorac Oncol; 2021 Oct; 16(10):1705-1717. PubMed ID: 34116230
[TBL] [Abstract][Full Text] [Related]
33. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.
Sato H; Soh J; Aoe K; Fujimoto N; Tanaka S; Namba K; Torigoe H; Shien K; Yamamoto H; Tomida S; Tao H; Okabe K; Kishimoto T; Toyooka S
Int J Oncol; 2019 Jun; 54(6):2139-2148. PubMed ID: 30942424
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis.
Pei D; Li Y; Liu X; Yan S; Guo X; Xu X; Guo X
Oncotarget; 2017 Feb; 8(8):13030-13038. PubMed ID: 28103581
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
36. Exhaled breath analysis using on-line preconcentration mass spectrometry for gastric cancer diagnosis.
Hong Y; Che X; Su H; Mai Z; Huang Z; Huang W; Chen W; Liu S; Gao W; Zhou Z; Tan G; Li X
J Mass Spectrom; 2021 Apr; 56(4):e4588. PubMed ID: 32633879
[TBL] [Abstract][Full Text] [Related]
37. Do linear logistic model analyses of volatile biomarkers in exhaled breath of cystic fibrosis patients reliably indicate Pseudomonas aeruginosa infection?
Španěl P; Sovová K; Dryahina K; Doušová T; Dřevínek P; Smith D
J Breath Res; 2016 Aug; 10(3):036013. PubMed ID: 27532768
[TBL] [Abstract][Full Text] [Related]
38. Confounding effect of benign pulmonary diseases in selecting volatile organic compounds as markers of lung cancer.
Wang M; Sheng J; Wu Q; Zou Y; Hu Y; Ying K; Wan H; Wang P
J Breath Res; 2018 Sep; 12(4):046013. PubMed ID: 30102249
[TBL] [Abstract][Full Text] [Related]
39. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
Nuvoli B; Sacconi A; Bottillo G; Sciarra F; Libener R; Maconi A; Carosi M; Piperno G; Mastropasqua E; Papale M; Camera E; Galati R
Biomed Pharmacother; 2024 Jun; 175():116662. PubMed ID: 38692064
[TBL] [Abstract][Full Text] [Related]
40. Increasing conclusiveness of clinical breath analysis by improved baseline correction of multi capillary column - ion mobility spectrometry (MCC-IMS) data.
Szymańska E; Tinnevelt GH; Brodrick E; Williams M; Davies AN; van Manen HJ; Buydens LM
J Pharm Biomed Anal; 2016 Aug; 127():170-5. PubMed ID: 26879424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
